On July 17, Everest Medicines fell 7.83% in regular trading, trading at HK$26.34/share, with turnover of HK$51.30 million.

On the news front, the company has no material negative announcements. The decline is primarily attributed to a broad-based selloff across the biotechnology sector. Key sector constituents saw significant losses, with AKESO down 11.1%, 3SBIO down 11.22%, Innovent Bio down 4.88%, SKB Bio down 5.95%, and BeiGene down 2.57%, reflecting substantial sector-wide selling pressure.

On July 15, Everest Medicines had risen 6.67% on the back of its EVER001 licensing deal closing with Travere Therapeutics and strong sector momentum. The current pullback is driven by short-term profit-taking following recent gains, compounded by the systematic sector correction in biotechnology names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)